Context Therapeutics Inc. ownership disclosure: Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl filed a joint Schedule 13G/A amendment reporting shared beneficial ownership of 2,238,496 shares of Context Therapeutics common stock, representing 2.44% of the class.
The filing states the percentage is calculated using 91,879,177 shares outstanding as of April 28, 2026 and shows shared voting and dispositive power over the reported shares. The Reporting Persons executed a Joint Filing Agreement dated May 15, 2026.
Positive
None.
Negative
None.
Insights
Large holder reports a passive, shared 2.44% stake.
The filing shows Great Point Partners, LLC and two individuals jointly report beneficial ownership of 2,238,496 shares, with shared voting and dispositive power. The stake is disclosed on a Schedule 13G/A, which typically indicates a passive investment intent.
Key dependencies include whether the position remains passive or converts to activist behavior; subsequent filings would show any change in status or voting arrangements.
Joint filing clarifies reporting responsibilities and shared authority.
The Joint Filing Agreement dated May 15, 2026 allocates filing responsibility among the reporting persons and notes shared responsibility for accuracy of each person's information. The cover-page data ties the percentage to 91,879,177 shares outstanding as of April 28, 2026.
Watch for future amendments or Schedule 13D if the reporting group acquires greater control or changes intentions; timing not stated in the excerpt.
Key Figures
Beneficial ownership:2,238,496 sharesPercent of class:2.44%Shares outstanding:91,879,177 shares+1 more
4 metrics
Beneficial ownership2,238,496 sharesreported on Schedule 13G/A
Percent of class2.44%based on shares outstanding as of April 28, 2026
Shares outstanding91,879,177 sharesas reported in issuer Annual Report on April 28, 2026
CUSIP21077P108Context Therapeutics common stock
Key Terms
Schedule 13G/A, Joint Filing Agreement, Shared dispositive power
3 terms
Schedule 13G/Aregulatory
"Amendment No. 7 to Schedule 13G/A cover pages and Item 1"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Joint Filing Agreementregulatory
"Joint Filing Agreement dated May 15, 2026 is filed as Exhibit A"
Shared dispositive powerfinancial
"Rows show Shared Dispositive Power 2,238,496.00 on cover pages"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)
Context Therapeutics Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
21077P108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
21077P108
1
Names of Reporting Persons
Great Point Partners, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,238,496.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,238,496.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,238,496.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.44 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
21077P108
1
Names of Reporting Persons
Dr. Jeffrey R. Jay, M.D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,238,496.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,238,496.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,238,496.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.44 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
21077P108
1
Names of Reporting Persons
Ms. Lillian Nordahl
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,238,496.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,238,496.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,238,496.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.44 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Context Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
2001 Market Street, Suite 3915, Suite #15, Philadelphia, Pennsylvania 19103
Item 2.
(a)
Name of person filing:
Great Point Partners, LLC
Dr. Jeffrey R. Jay, M.D.
Ms. Lillian Nordahl
The Reporting Persons have entered into a Joint Filing Agreement, dated May 15, 2026, a copy of which is filed with this SCHEDULE 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is
165 Mason Street, 3rd Floor
Greenwich, CT 06830
(c)
Citizenship:
Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States.
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
21077P108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
2,238,496
(b)
Percent of class:
2.44%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
2,238,496
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
2,238,496
Item 4
The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference.
The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 91,879,177 shares outstanding, as reported by the Issuer in its Annual Report to Security Holders filed with the Securities and Exchange Commission (the "SEC") on April 28, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 4.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Great Point Partners, LLC
Signature:
/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:
Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Date:
05/15/2026
Dr. Jeffrey R. Jay, M.D.
Signature:
/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:
Dr. Jeffrey R. Jay, M.D
Date:
05/15/2026
Ms. Lillian Nordahl
Signature:
/s/ Ms. Lillian Nordahl
Name/Title:
Ms. Lillian Nordahl
Date:
05/15/2026
Exhibit Information
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned hereby agree as follows:
(i) Each of them is individually eligible to use the SCHEDULE 13G/A to which this Exhibit is attached, and such SCHEDULE 13G/A is filed on behalf of each of them; and
(ii) Each of them is responsible for the timely filing of such SCHEDULE 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
Dated: May 15, 2026
Great Point Partners, LLC
By: /s/ Dr. Jeffrey R. Jay, M.D.
Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
Dr. Jeffrey R. Jay, M.D.
By: /s/ Dr. Jeffrey R. Jay, M.D.
Dr. Jeffrey R. Jay, M.D.
Ms. Lillian Nordahl
By: /s/ Ms. Lillian Nordahl
Ms. Lillian Nordahl
What stake does Great Point Partners report in CNTX?
Great Point Partners and joint filers report 2,238,496 shares, equal to 2.44% of common stock, based on 91,879,177 shares outstanding as of April 28, 2026. The ownership is reported as shared voting and dispositive power.
Does this Schedule 13G/A indicate activist intent for CNTX?
No explicit activist intent is stated; the filing is a Schedule 13G/A, which commonly reflects a passive position. The document does not state any plan to change control or engage in activism.
Who are the reporting persons on the CNTX filing?
The reporting persons are Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, who executed a Joint Filing Agreement dated May 15, 2026 to file jointly under Rule 13d-1(k)(1).
What voting and dispositive powers are reported for this CNTX stake?
The filing shows 0 shares with sole voting or dispositive power and 2,238,496 shares with shared voting and shared dispositive power, as reported on the cover pages.
What share count did Context Therapeutics report for outstanding shares?
The percentage is calculated using 91,879,177 shares outstanding, as reported in the issuer's Annual Report referenced in the filing and dated April 28, 2026.
